Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Haematol ; 96(1): 27-35, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25703164

ABSTRACT

OBJECTIVE: Post-transplant cyclophosphamide is increasingly used as graft-versus-host disease (GvHD) prophylaxis in the setting of bone marrow transplantation. No data have been published on the use of single-agent GvHD prophylaxis with post-transplant cyclophosphamide in the setting of peripheral blood stem cell transplantation (PBSCT). METHODS: In a phase II trial, 11 patients with myeloma or lymphoma underwent conditioning with fludarabine and busulfan followed by T-replete PBSCT and application of 50 mg/kg/d of cyclophosphamide on day+3 and +4 without other concurrent immunosuppression (IS). RESULTS: Median time to leukocyte, neutrophil, and platelet engraftment was 18, 21, and 18 d. The incidence of grade II-IV and grade III-IV GvHD was 45% and 27%, with a non-relapse mortality (NRM) of 36% at one and 2 yr. After median follow-up of 927 d, overall and relapse-free survival was 64% and 34%. Three patients did not require any further systemic IS until day+100 and thereafter. Analysis of immune reconstitution demonstrated rapid T- and NK-cell recovery. B- and CD3+/CD161+NK/T-cell recovery was superior in patients not receiving additional IS. CONCLUSION: Post-transplant cyclophosphamide as sole IS in PBSCT is feasible and allows rapid immune recovery. Increased rates of severe acute GvHD explain the observed NRM and may advise a temporary combination partner such as mTor-inhibitors in the PBSCT setting.


Subject(s)
Cyclophosphamide/administration & dosage , Graft vs Host Disease/prevention & control , Hematologic Neoplasms/therapy , Peripheral Blood Stem Cell Transplantation , Adult , Allografts , Cyclophosphamide/adverse effects , Female , Graft vs Host Disease/blood , Graft vs Host Disease/etiology , Hematologic Neoplasms/blood , Humans , Male , Middle Aged
2.
Biochem J ; 457(1): 207-14, 2014 Jan 01.
Article in English | MEDLINE | ID: mdl-24151981

ABSTRACT

RNF4 (RING finger protein 4) is a STUbL [SUMO (small ubiquitin-related modifier)-targeted ubiquitin ligase] controlling PML (promyelocytic leukaemia) nuclear bodies, DNA double strand break repair and other nuclear functions. In the present paper, we describe that the sequence and spacing of the SIMs (SUMO-interaction motifs) in RNF4 regulate the avidity-driven recognition of substrate proteins carrying SUMO chains of variable length.


Subject(s)
Nuclear Proteins/chemistry , Nuclear Proteins/metabolism , Protein Interaction Domains and Motifs , SUMO-1 Protein/metabolism , Sumoylation/physiology , Transcription Factors/chemistry , Transcription Factors/metabolism , Amino Acid Sequence , Binding Sites , HeLa Cells , Humans , Molecular Sequence Data , Protein Binding/physiology , Protein Interaction Domains and Motifs/physiology , Saccharomyces cerevisiae , Substrate Specificity
3.
J Clin Oncol ; 31(5): e59-63, 2013 Feb 10.
Article in English | MEDLINE | ID: mdl-23269992
4.
Crit Care Med ; 40(9): 2654-61, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22743778

ABSTRACT

OBJECTIVE: To investigate the effects of proportional assist ventilation, variable pressure support, and conventional pressure support ventilation on lung function and damage in experimental acute lung injury. DESIGN: : Randomized experimental study. SETTING: University hospital research facility. SUBJECTS: : Twenty-four juvenile pigs. INTERVENTIONS: Pigs were anesthetized, intubated, and mechanically ventilated. Acute lung injury was induced by saline lung lavage. After resuming of spontaneous breathing, animals were randomly assigned to 6 hrs of assisted ventilation with pressure support ventilation, proportional assist ventilation, or variable pressure support (n = 8 per group). Mean tidal volume was kept at ≈6 mL/kg in all modes. MEASUREMENTS AND MAIN RESULTS: Lung functional parameters, distribution of ventilation by electrical impedance tomography, and breathing patterns were analyzed. Histological lung damage and pulmonary inflammatory response were determined postmortem. Variable -pressure support and proportional assist ventilation improved oxygenation and venous admixture compared with pressure support ventilation. Proportional assist ventilation led to higher esophageal pressure time product than variable pressure support and pressure support ventilation, and redistributed ventilation from central to dorsal lung regions compared to pressure support ventilation. Variable pressure support and proportional assist ventilation yielded higher tidal volume variability than pressure support ventilation. Such pattern was deterministic (self-organized) during proportional assist ventilation and stochastic (random) during variable pressure support. Subject-ventilator synchrony as well as pulmonary inflammatory response and damage did not differ among groups. CONCLUSIONS: In a lung lavage model of acute lung injury, both variable pressure support and proportional assist ventilation increased the variability of tidal volume and improved oxygenation and venous admixture, without influencing subject-ventilator synchrony or affecting lung injury compared with pressure support ventilation. However, variable pressure support yielded less inspiratory effort than proportional assist ventilation at comparable mean tidal volumes of 6 mL/kg.


Subject(s)
Acute Lung Injury/therapy , Interactive Ventilatory Support/methods , Positive-Pressure Respiration/methods , Ventilator-Induced Lung Injury/pathology , Acute Lung Injury/mortality , Acute Lung Injury/pathology , Animals , Disease Models, Animal , Hemodynamics/physiology , Inflammation Mediators/metabolism , Interactive Ventilatory Support/adverse effects , Positive-Pressure Respiration/adverse effects , Pulmonary Gas Exchange , RNA, Messenger/analysis , Random Allocation , Respiratory Function Tests , Risk Assessment , Sensitivity and Specificity , Swine , Treatment Outcome , Ventilator-Induced Lung Injury/physiopathology
5.
Methods Mol Biol ; 832: 81-92, 2012.
Article in English | MEDLINE | ID: mdl-22350877

ABSTRACT

Posttranslational modification of proteins with the small ubiquitin-related modifier (SUMO) has been implicated in many important physiological functions, including the regulation of transcription and DNA repair. In most cases, only a small fraction of the total cellular amounts of a given protein is sumoylated at a certain point in time. Sensitive detection of sumoylated forms of proteins by western blotting is, therefore, an important step in the identification and/or characterization of a protein control by sumoylation. Polysumoylated proteins are recognized and targeted to the proteasome by specific ubiquitin ligases bearing SUMO interaction motifs. Sumoylation itself is reversible by the action of desumoylating enzymes. Their activities cause a rapid loss of SUMO conjugates in most standard cell extracts. To preserve SUMO-protein conjugates, therefore, a preparation of extracts under denaturing conditions is recommended. Here, we describe the application of an alkaline lysis procedure and a western blot protocol for the analysis of SUMO conjugates in yeast and human cells. In addition, we describe the application of another extraction procedure combined with immobilized metal affinity chromatography for the analysis of ubiquitin-SUMO hybrid conjugates from yeast and human cells.


Subject(s)
Small Ubiquitin-Related Modifier Proteins/analysis , Small Ubiquitin-Related Modifier Proteins/metabolism , Ubiquitin/analysis , Ubiquitin/metabolism , Blotting, Western/methods , Chromatography, Affinity/methods , Humans , Saccharomyces cerevisiae , Small Ubiquitin-Related Modifier Proteins/chemistry , Sumoylation , Ubiquitin/chemistry , Ubiquitin-Conjugating Enzymes/metabolism , Ubiquitin-Protein Ligases/metabolism
6.
Ann Hematol ; 91(1): 47-55, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21584670

ABSTRACT

Lower dosage of total body irradiation (TBI) and chemotherapy in reduced-intensity conditioning (RIC) regimens prior to allogeneic stem cell transplantation have reduced the toxicity of the conditioning and non-relapse mortality. The FLAMSA-RIC protocol for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome has shown promising results in refractory disease as well as in first complete remission. Still, the RIC protocol containing 4 Gy TBI/cyclophosphamide/anti-thymocyte globulin (ATG) implicates acute toxicity mainly due to TBI preventing its usage in patients with advanced age and/or severe co-morbidities. To increase feasibility and safety of the conditioning, we substituted TBI with treosulfan. Seventeen patients with relapsed or high-risk AML and either advanced age or concomitant disease were treated within a preparative regimen containing a 4-day course of chemotherapy (FLAMSA) followed by RIC comprising of treosulfan, cyclophosphamide, and ATG. After median follow-up of 12 months, the estimated incidences of relapse and non-relapse mortality were 25% and 20%, respectively. One-year overall survival was 62%. In conclusion, FLAMSA-treosulfan/cyclophosphamide/ATG is an intermediate intensity conditioning regimen with acceptable non-relapse mortality for patients with relapsed or high-risk AML. Substituting TBI with treosulfan provides an alternative to treat elderly patients or patients with severe co-morbidities when TBI appears not feasible due to the potential of increased toxicity.


Subject(s)
Antilymphocyte Serum/therapeutic use , Antineoplastic Agents, Alkylating/therapeutic use , Busulfan/analogs & derivatives , Cyclophosphamide/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Immunosuppressive Agents/therapeutic use , Leukemia, Myeloid, Acute/therapy , Transplantation Conditioning/methods , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Busulfan/therapeutic use , Disease-Free Survival , Female , Humans , Leukemia, Myeloid, Acute/prevention & control , Male , Middle Aged , Recurrence , Transplantation, Homologous/methods , Whole-Body Irradiation/adverse effects
7.
FEBS Lett ; 582(21-22): 3174-8, 2008 Sep 22.
Article in English | MEDLINE | ID: mdl-18708055

ABSTRACT

We have recently reported that poly-SUMO-2/3 conjugates are subject to a ubiquitin-dependent proteolytic control in human cells. Here we show that arsenic trioxide (ATO) increases SUMO-2/3 modification of promyelocytic leukemia (PML) leading to its subsequent ubiquitylation in vivo. The SUMO-binding ubiquitin ligase RNF4 mediates this modification and causes disruption of PML nuclear bodies upon treatment with ATO. Reconstitution of SUMO-dependent ubiquitylation of PML by RNF4 in vitro and in a yeast trans vivo system revealed a preference of RNF4 for chain forming SUMOs. Polysumoylation of PML in response to ATO thus leads to its recognition and ubiquitylation by RNF4.


Subject(s)
Antineoplastic Agents/pharmacology , Arsenicals/pharmacology , Leukemia, Promyelocytic, Acute/metabolism , Nuclear Proteins/metabolism , Oxides/pharmacology , Small Ubiquitin-Related Modifier Proteins/metabolism , Transcription Factors/metabolism , Ubiquitination/drug effects , Ubiquitins/metabolism , Arsenic Trioxide , Cell Line, Tumor , Down-Regulation , Humans , Proteasome Endopeptidase Complex/metabolism
8.
Leuk Lymphoma ; 43(11): 2139-43, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12533039

ABSTRACT

High-dose methotrexate (HDMTX) is a component of many cancer treatment regimens. Despite careful management, delayed renal clearance, followed by extremely high serum levels with potentially life-threatening toxicity can occur. In the present study, we report our results of carboxypeptidase-G2 (CPDG2) rescue in 8 patients with delayed methotrexate elimination and renal impairment after HDMTX therapy for lymphoma or osteosarcoma. A dose of 50 U/kg CPDG2 was administered. MTX plasma levels decreased rapidly and recovery of renal function was observed in all patients. No patient developed severe WHO grade 4 MTX toxicity. CPDG2 provides an alternative route of MTX elimination by converting it to inactive and non-toxic metabolites. CPDG2 rescue was well tolerated, safe and very effective in preventing severe or life-threatening MTX toxicity.


Subject(s)
Methotrexate/toxicity , Neoplasms/drug therapy , gamma-Glutamyl Hydrolase/administration & dosage , Adult , Antidotes/administration & dosage , Female , Humans , Kidney Diseases/chemically induced , Lymphoma/complications , Lymphoma/drug therapy , Male , Methotrexate/blood , Methotrexate/pharmacokinetics , Middle Aged , Neoplasms/complications , Osteosarcoma/complications , Osteosarcoma/drug therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...